GENMARK DIAGNOSTICS INC's ticker is GNMK and the CUSIP is 372309104. A total of 90 filers reported holding GENMARK DIAGNOSTICS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $91,000 | – | 3,834 | +136.2% | 0.00% | – |
| Q4 2020 | $0 | – | 1,623 | -86.6% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 12,099 | +327.4% | 0.00% | – |
| Q2 2020 | $41,000 | -81.4% | 2,831 | -94.7% | 0.00% | – |
| Q1 2020 | $220,000 | +2344.4% | 53,558 | +3222.5% | 0.00% | – |
| Q3 2019 | $9,000 | -40.0% | 1,612 | -34.4% | 0.00% | – |
| Q2 2019 | $15,000 | -40.0% | 2,457 | -31.9% | 0.00% | – |
| Q1 2019 | $25,000 | -19.4% | 3,610 | +37.7% | 0.00% | -100.0% |
| Q2 2017 | $31,000 | +14.8% | 2,622 | +23.0% | 0.00% | 0.0% |
| Q1 2017 | $27,000 | +350.0% | 2,132 | +326.4% | 0.00% | – |
| Q4 2016 | $6,000 | +50.0% | 500 | +36.2% | 0.00% | – |
| Q3 2016 | $4,000 | -92.6% | 367 | -94.2% | 0.00% | -100.0% |
| Q2 2016 | $54,000 | +68.8% | 6,297 | +0.9% | 0.00% | +33.3% |
| Q1 2016 | $32,000 | +700.0% | 6,243 | +995.3% | 0.00% | – |
| Q4 2015 | $4,000 | +300.0% | 570 | +185.0% | 0.00% | – |
| Q2 2015 | $1,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 3,500,000 | $25,725,000 | 3.13% |
| CADIAN CAPITAL MANAGEMENT, LP | 3,830,399 | $28,153,000 | 1.28% |
| Mesirow Financial Investment Management, Inc. | 33,001 | $243,000 | 1.25% |
| Bellevue Group AG | 1,339,502 | $9,845,000 | 0.62% |
| NEEDHAM INVESTMENT MANAGEMENT LLC | 260,000 | $1,912,000 | 0.58% |
| Lyon Street Capital, LLC | 109,850 | $807,000 | 0.50% |
| Private Wealth Partners, LLC | 300,000 | $2,205,000 | 0.34% |
| Penn Capital Management Company, LLC | 455,064 | $3,345,000 | 0.25% |
| HighTower Advisors, LLC | 2,337,132 | $17,179,000 | 0.12% |
| Schonfeld Strategic Advisors LLC | 376,000 | $2,763,000 | 0.12% |